In Bloomberg Law, Margaux Hall Analyzes Litigation Influence in Medicare Drug Price Negotiation Program

The government recently published prices for the first 10 drug prices negotiated for the Medicare Drug Price Negotiation Program, claiming these will result in vast savings for government spending and beneficiary costs.  The published list prices emerge under the landmark Inflation Reduction Act, which allowed the U.S. to set the prices of some of the most expensive and widely used drugs covered under Medicare.

The unveiled prices may serve to alter the landscape for litigation claims that the program causes financial harm to drugmakers, and related questions regard whether actual negotiation took place.

In a Bloomberg Law article, health care partner Margaux Hall, who leads the firm’s drug pricing and price reporting group, said that drug prices were issued for the first year may influence the litigation that is underway, whether through further filings or briefing on the impact of the actual price cuts.

“There are certain claims that could be strengthened if the government’s more aggressive in its price cuts,” said Margaux.